NVN Liquidation (OTCPK:NOVN.Q) - Cours de l'action, nouvelles et analyse

NOVN.Q Aperçu des actions

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Plus de détails

NOVN.Q analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	0/6
Dividendes	0/6

Récompenses

Le chiffre d'affaires a augmenté de 512.7% au cours de l'année écoulée

Analyse des risques

Cours de l'action très volatil au cours des 3 derniers mois

Capitaux propres négatifs

N'a pas de capitalisation boursière significative ( $28 )

Les derniers rapports financiers datent de plus de 6 mois

NVN Liquidation, Inc. Concurrents

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Baudax Bio

OTCPK:BXRX.Q

US$52.0

RVL Pharmaceuticals

OTCPK:RVLP.Q

US$11.1k

Halo Collective

OTCPK:HCAN.F

US$150.0

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour NVN Liquidation
Historique des cours de bourse
Prix actuel de l'action	US$0.000001
Plus haut sur 52 semaines	US$1.38
Plus bas sur 52 semaines	US$0.000001
Bêta	1.65
1Variation sur 1 mois	-99.88%
Variation sur 3 mois	-99.00%
Variation sur 1 an	-100.00%
3Variation sur 3 ans	-100.00%
Variation sur 5 ans	-100.00%
Évolution depuis l'introduction en bourse	-100.00%

Nouvelles et mises à jour récentes

Recent updates

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Jun 07

Novan Q2 2022 Earnings Preview

Aug 10

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Jul 19

Rendement pour les actionnaires

	NOVN.Q	US Pharmaceuticals	US Marché
7D	-99.9%	1.6%	2.2%
1Y	-100.0%	9.9%	31.6%

Rendement vs Industrie: NOVN.Q a sous-performé le secteur US Pharmaceuticals qui a rapporté 9.9 % au cours de l'année écoulée.

Rendement vs marché: NOVN.Q a sous-performé le marché US qui a rapporté 31.6 % au cours de l'année écoulée.

Volatilité des prix

Is NOVN.Q's price volatile compared to industry and market?
NOVN.Q volatility
NOVN.Q Average Weekly Movement	1,535.8%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: Le cours de l'action de NOVN.Q a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de NOVN.Q a diminué de 1617% à 1536% au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2006	90	Scott Plesha	www.novan.com

NVN Liquidation, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de NVN Liquidation se comparent-ils à sa capitalisation boursière ?
NOVN.Q statistiques fondamentales
Capitalisation boursière	US$28.00
Bénéfices(TTM)	-US$32.05m
Recettes(TTM)	US$24.92m

0.0x

Ratio P/S

0.0x

Ratio P/E

Le site NOVN.Q est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
NOVN.Q compte de résultat (TTM)
Recettes	US$24.92m
Coût des recettes	US$24.45m
Marge brute	US$473.00k
Autres dépenses	US$32.52m
Les revenus	-US$32.05m

Derniers bénéfices déclarés

Mar 31, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.14
Marge brute	1.90%
Marge bénéficiaire nette	-128.61%
Ratio dettes/capitaux propres	-1,164.1%

Quelles ont été les performances à long terme de NOVN.Q?

Voir les performances historiques et les comparaisons

NOVN.Q Aperçu des actions

Récompenses

Analyse des risques

NVN Liquidation, Inc. Concurrents

OTCPK:PLXP.Q

US$30.0

OTCPK:BXRX.Q

US$52.0

OTCPK:RVLP.Q

US$11.1k

OTCPK:HCAN.F

US$150.0

Historique des prix et performances

Nouvelles et mises à jour récentes

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Price target decreased by 12% to US$11.50

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Price target decreased by 12% to US$11.50

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 14% to US$11.50

Consensus EPS estimates fall by 16%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 13% to US$12.67

Forecast to breakeven in 2025

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novan Q2 2022 Earnings Preview

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $40.000004 million.

Novan shares under pressure after proposing capital raise

Novan, Inc. Reports Positive Topline Results from Pivotal Phase 3 Trial of Sb206 in Patients with Molluscum Contagiosum

Novan, Inc. Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

Novan, Inc. Announces Results from Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan’s NVN4100 shows antimicrobial effect against bacteria in animal health

Novan, Inc. Announces Final Week-12 Visit for Last Patient in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Contemplates Bankruptcy

Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

Novan regains Nasdaq compliance for minimum bid price requirement

Novan Updates Enrollment for Its B-SIMPLE4 Pivotal Phase 3 Study Evaluating SB206

Novan Exceeds 60% Enrollment in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan Receives Approval from the Listing Qualifications Department of the Nasdaq Stock Market

Novan EPS in-line, beats on revenue

Novan, Inc. Announces Positive in vitro Results Showing the Potential Efficacy of Its NITRICIL™ Platform Technology as an Antiviral Against SARS-CoV-2 the Virus That Causes COVID-19

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Novan, Inc. May File for Bankruptcy

Earnings released

Price target lowered to US$2.75

Novan, Inc.(NasdaqGM:NOVN) dropped from Russell Microcap Value Index

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

NVN Liquidation, Inc. Résumé des fondamentaux

0.0x

0.0x

Bénéfices et recettes